Neurogene Inc

For the period ended Dec 31, 2023. Filed Mar 18, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 18, 2024

NGNE$26.00+2.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Page
Part I
	Item 1. Business	3
	Item 1A. Risk Factors	43
	Item 1B. Unresolved Staff Comments	89
	Item 1C. Cybersecurity	89
	Item 2. Properties	90
	Item 3. Legal Proceedings	90
	Item 4. Mine Safety Disclosures	90
Part II
	Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	91
	Item 6. [Reserved]	91
	Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations	91
	Item 7A. Quantitative and Qualitative Disclosures About Market Risk	106
	Item 8. Financial Statements and Supplementary Data	107
	Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	134
	Item 9A. Controls and Procedures	134
	Item 9B. Other Information	135
	Item 9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections.	135
Part III
	Item 10. Directors, Executive Officers and Corporate Governance	136
	Item 11. Executive Compensation	136
	Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	136
	Item 13. Certain Relationships and Related Transactions, and Director Independence	136
	Item 14. Principal Accountant Fees and Services	136
Part IV
	Item 15. Exhibits and Financial Statement Schedules	137
Signatures	141

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Tableof Contents